Skip to main content
. 2021 Mar 25;95(8):e02415-20. doi: 10.1128/JVI.02415-20

FIG 9.

FIG 9

IFN production upon SARS-CoV-2 replication does not protect Calu-3 and A549-ACE2 cells against infection. (A) CTRL, RIG-I, MDA-5, and MAVS Calu-3 knockout (KO) cells were infected with SARS-CoV-2 at MOI 0.05 (as in Fig. 5B and C) and viral production was measured 48 h later by plaque assays on Vero E6 cells. (B) CTRL and IRF9 Calu-3 KO cells were generated and selected. Cells were infected with SARS-CoV-2 at the indicated MOIs and viral replication was evaluated 48 h later by RdRp RT-qPCR. (C) CTRL and IRF9 KO cells were pretreated or not with IFN for 48 h, lysed, and the expression levels of IFITM3, RIG-I, MX1, and actin were analyzed by immunoblotting. (D) CTRL and JAK1 A549-ACE2 knockout cells were generated and selected. Cells were infected with SARS-CoV-2 at MOI 0.0005 and viral replication was measured 48 h later using RdRp RT-qPCR. (E) CTRL and JAK1 A549-ACE2 knockout cells were pretreated or not with IFN for 48 h, lysed, and the expression levels of IFITM3, RIG-I, and MX1 were analyzed by immunoblotting, with actin serving as a loading control. (F) Calu-3 cells were infected with SARS-CoV-2 at the indicated MOIs after a 24-h pretreatment with IFN or not, or were subsequently treated with IFN at 4 h, 8 h, or 24 h postinfection. Viral replication was measured at 48 h postinfection using RdRp RT-qPCR. The means of two (A and D) or three (B and F) independent experiments are shown, with error bars representing the SD. Representative immunoblots (C and E) are shown.

HHS Vulnerability Disclosure